Designation of Sodium Phenylbutyrate (TBA) as an orphan drug by Orpharma Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, serves to regulate therapeutic goods, including medicines, medical devices, and blood and blood components. This Act was introduced to address the need for a comprehensive framework that ensures the safety, quality, and efficacy of therapeutic goods available in Australia. One of the significant aspects of this legislation is the ability to designate orphan drugs, which are intended to treat rare diseases or conditions that affect a small number of people. In this context, the Therapeutic Goods Administration, acting under the authority granted by the Therapeutic Goods Regulations 1990, has designated Sodium Phenylbutyrate (TBA) as an orphan drug for the treatment of urea cycle disorders, as announced on 22 March 2017. This designation aims to facilitate the development and availability of necessary treatments for rare medical conditions by providing certain incentives and streamlined regulatory processes.

Scope and Application

The Therapeutic Goods Act 1989, through the designation of Sodium Phenylbutyrate (TBA) as an orphan drug, applies to the pharmaceutical product itself, its sponsor, and ultimately to individuals who will benefit from this treatment. Specifically, this legislation applies to Orpharma Pty Ltd as the sponsor of Sodium Phenylbutyrate (TBA), which is intended for the treatment of urea cycle disorders. The Act's reach is national, falling under the jurisdiction of the Commonwealth of Australia as administered by the Therapeutic Goods Administration. There are no stated exclusions or exemptions in this specific designation; however, the broader applicability of the Therapeutic Goods Act encompasses a wide range of therapeutic goods, subject to various regulatory controls and requirements. The Act's application can be extended or restricted through subordinate instruments such as the Therapeutic Goods Regulations 1990, which provide further detail on the approval and regulation of therapeutic goods, including orphan drugs.

Key Provisions

The Therapeutic Goods Act 1989 has been amended to designate Sodium Phenylbutyrate (TBA) as an orphan drug for the treatment of urea cycle disorders (section 16J of the Therapeutic Goods Regulations 1990). This designation is made under the authority of Dr Anthony Gill, who is acting as the Delegate of the Secretary for the purposes of the Regulations (section 16J(2)). The orphan drug designation applies to the tablet form of Sodium Phenylbutyrate (TBA) specifically for this indication, and the sponsor responsible for this therapeutic good is Orpharma Pty Ltd. The obligations imposed by this designation include the sponsor’s responsibility to ensure that Sodium Phenylbutyrate (TBA) meets the necessary quality, safety, and efficacy standards as outlined in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. The sponsor must also comply with any specific requirements related to the orphan drug designation, such as providing additional data or documentation to support the therapeutic benefits of the drug for patients with urea cycle disorders. Additionally, the sponsor is required to maintain records of all relevant information and be prepared to provide access to these records upon request by the Therapeutic Goods Administration. Failure to comply with the requirements of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 may result in civil or criminal penalties. For example, an individual or entity that knowingly makes a false or misleading representation in relation to a therapeutic good may be liable for a civil penalty of up to $222,222 for a corporation and $44,444 for an individual (section 42AA). Criminal penalties may also apply, with maximum penalties ranging from fines to imprisonment, depending on the severity of the breach and the intent behind it. It is essential for the sponsor and other parties involved in the manufacture, supply, or distribution of Sodium Phenylbutyrate (TBA) to be aware of their obligations under the Act and the Regulations to avoid any potential legal consequences.